The US Food and Drug Administration has approved a new drug to treat patients with multidrug-resistant HIV-1, the first therapy in more than a decade with a new mechanism of action. Developed by Taipei, Taiwan–based TaiMed Biologics, Trogarzo (ibalizumab-uiyk) is a humanized monoclonal antibody that binds…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 4 APRIL 2018 291